COMPARATIVE ANALYSIS OF THE INFLAMMATORY RESPOND OF THE VASCULAR WALL AFTER IMPLANTATION OF BIORESORBABLE SCAFFOLDS AND EVEROLIMUS COVERED STENTS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE

Aim - to conduct a comparative analysis of markers of inflammatory reaction of the vascular wall in patients with stable coronary artery disease (CAD) after implantation of bioresorbable scaffolds (BS) and everolimus-eluting stents during short observation period. Material and methods. 20 patients with stable CAD and mono-vessel coronary bed lesion with indication to percutaneous coronary intervention (PCI) were studied. Group 1 consisted of 9 patients with implanted stent covered with everolimus; group 2 consisted of 11 patients with implanted BS. Biochemical inflammatory markers were defined at the admission time, in 1 day, 4 days and 1 month after PCI. Results. In 1 day after PCI both groups expectedly showed cytokine level growth, including interleukin 6 (IL-6), as a respond to the vascular wall lesion with the following decrease in 4 days to the initial level. On the second day after PCI serum content of matrix metalloproteinases 9 (MMPs-9) was increased in groups 1 and 2 of patients. Lowering of MMPs-9 with no reaching the initial level in 1 month was noticed only in group 2, whereas group 1 kept high concentration of MMPs-9. The comparable groups had the maximum content of soluble CD40-ligand (sCD40L) on the 4th day with a little lowering after 1 month only in group 2. High level of high-sensitive C-reactive protein (CRP) remained during the entire follow-up period in both groups. Conclusion: Patients with stable CAD after implantation of BS and everolimus covered stents did not have any differences in dynamics of mediators of acute inflammation phase. Persistent high levels of MMPs-9, sCD40L and also elevated concentration of CRP assume prolonged character of the vascular wall inflammatory respond, being more expressed after implantation of everolimus covered stents.

coronary artery disease, angioplasty, inflammation, bioresorbable scaffolds

1. Барбараш О.Л., Осокина А.В. Роль маркеров системы CD40/CD40L в прогнозировании сердечно-сосудистых событий при коронарном атеросклерозе // Патол. кровообращения и кардиохирургия. 2011. (3). 89-93.

2. Плечев В.В., Николаева И.Е., Бузаев И.В., Загитов И.Г., Ризберг Р.Ю., Яманаева И.Е. Биорезорбируемые внутрисосудистые каркасы. Обзорная статья // Креатив. хирургия и онкология. 2017. 7. (4). 53-62.

3. Проскуряков А.И., Мироненко С.П., Осиев А.Г. Клинико-иммунологические аспекты формирования рестеноза после коронарного стентирования при ИБС // Мед. и образование в Сибири. 2013. (3). https://readera.ru/14299210.

4. Семенихин А.А., Грачев Н.И., Маркелова Е.В., Турмова Е.П. Анализ иммунобиохимических маркеров в развитии рестеноза после стентирования коронарных артерий у пациентов со стабильной стенокардией // Здоровье и образование в XXI в. 2016. 18. (2). 626-635.

5. Bibek S.B., Xie Y., Gao J.J., Wang Z., Wang J.F., Geng D.F. Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysisof longitudinal studies // Inflammation. 2015. 38. (1). 159-169.

6. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., Meyer J., Cambien F., Tiret L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease // Circulation. 2003. 107. 1579-1585.

7. Bourantas C.V., Papafaklis M.I., Garcia-Garcia H.M., Farooq V., Diletti R., Muramatsu T., Zhang Y., Kalatzis F.G., Naka K.K., Fotiadis D.I., Onuma Y., Michalis L.K., Serruys P.W. Short- and long-term implications of a bioresorbable vascular scaffold implantation on the local endothelial shear stress patterns // JACC Cardiovasc. Interv. 2014. 7. (1). 100-101.

8. Finn A.V., Kolofgie F.D., Harnek J. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents // Circulation. 2005. 112. (2). 270-78.

9. Gao J., Liu Y., Cui R.Z., Mao Y.M., Zhou J., Chen Q., Zhao F.M., Yang G.M. Relationship of interleukin-6-572C/G promoter polymorphism and serum levels to post-percutaneous coronary intervention restenosis // Chin. Med. J. 2013. 126. (6). 1019-1025.

10. Katsaros K.M., Kastl S.P., Zorn G., Maurer G., Wojta J., Huber K., Christ G., Speidl W.S. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9 // JACC Cardiovasc. Interv. 2010. 3. (1). 90-97.

11. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells // Circulation. 2000. 102. (6). 2165-2168.

12. Samady H., Eshtehardi P., McDaniel M.C., Suo J., Dhawan S.S., Maynard C., Timmons L.H., Quyyumi A.A., Giddens D.P. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease // Circulation. 2011. 124. (7). 779-788.

13. Serruys P.W., Garcia-Garcia H.M., Onuma Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade? // Eur. Heart J. 2012. 33. (1). 16-25.

14. Simon D.I. Inflammation and vascular injury: basic discovery to drug development // Circ. J. 2012. 76. 1811-1818.

15. Sorrentino S., Giustino G., Mehran R., Kini A.S., Sharma S.K., Faggioni M., Farhan S., Vogel B., Indolfi C., Dangas G.D. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents // J. Am. Coll. Cardiol. 2017. 69. (25). 3055-3066.

16. Tuomisto K., Jousilahti P., Sundvall J., Pajunen P., Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study // Thromb. Haemost. 2006. 95. (3). 511-518.

17. Walter D.H., Fichtlschere S., Sellwig M., Auch-Schwelk W., Schachinger V., Zeiher A.M. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation // J. Am. Coll. Cardiol. 2001. 37. 839-846.

18. Williams N., Bertoncello I., Jackson H., Arnold J., Kavnoudias H. The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production // Ciba Found Symp. 1992. 167. 160-170.